Consolidated Statements of Stockholders' Equity (USD $)	Preferred Stock $.001 Par Value Series B	Common Stock $.001 Par Value USD ($)	Additional Paid-in Capital USD ($)	Other Comprehensive Income USD ($)	Accumulated Deficit USD ($)	Total USD ($)
Balance at Dec. 31, 2009		$ 398,000	$ 51,692,000	$ 151,000	$ (53,089,000)	$ (848,000)
Balance (in shares) at Dec. 31, 2009	49,999	397,452,926
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares for cash		3,000	228,000			231,000
Issuance of shares for cash (in shares)		2,950,000
Issuance of shares related to required deposit on Acquisition Option Agreement		7,000	453,000			460,000
Issuance of shares related to required deposit on Acquisition Option Agreement (in shares)		7,667,000
Issuance of shares for services Rendered		4,000	231,000			235,000
Issuance of shares for services Rendered (in shares)		3,700,000
Vesting of stock warrants			122,000			122,000
Comprehensive loss				(86,000)		(86,000)
Net loss					(43,000)	(43,000)
Balance at Dec. 31, 2010		412,000	52,726,000	65,000	(53,132,000)	71,000
Balance (in shares) at Dec. 31, 2010	49,999	411,769,926
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares for cash		2,000	98,000			100,000
Issuance of shares for cash (in shares)		2,000,000
Issuance of shares related to acquisition of Senior Scientific and Scientific Nanomedicine		14,000	885,000			899,000
Issuance of shares related to acquisition of Senior Scientific and Scientific Nanomedicine (in shares)		14,001,000
Issuance of shares for services Rendered		12,000	792,000			804,000
Issuance of shares for services Rendered (in shares)		12,287,683
Recognition of debt discount on warrants associated with debt			75,000			75,000
Stock option award - fully vested			408,000			408,000
Comprehensive loss				(33,000)		(33,000)
Net loss					(2,287,000)	(2,287,000)
Balance at Dec. 31, 2011		$ 440,000	$ 54,984,000	$ 32,000	$ (55,419,000)	$ 37,000
Balance (in shares) at Dec. 31, 2011	49,999	440,058,609